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Human cystatin C is considered the physiologically
most important inhibitor of endogenous papain-like
cysteine proteases. We present here an unexpected
function of cystatin C. Instead of acting as an inhibi-
tor, cystatin C acts as a facultative, endogenous co-
factor for the papain-like IgG-cleaving enzyme IdeS
of the human pathogen Streptococcus pyogenes.
IdeS activity is not dependent on cystatin C, but is
significantly enhanced in the presence of cystatin
C. We report a protease inhibitor that accelerates
the activity of its putative target protease and
a unique example of how a host protease inhibitor
is ‘‘hijacked’’ by a bacterial protease to increase its
activity. This finding has important implications for
the view on protease-inhibitor interactions, and is rel-
evant to consider in the therapeutic use of protease
inhibitors.
INTRODUCTION
Proteases play significant roles in all aspects of cellular life, in-
cluding cell division, metabolic and catabolic processes, protein
translocation, immune defense, and apoptosis (Rawlings et al.,
2004). To prevent proteolytic activity that might be harmful for
the living organism, the activity of different proteases has to be
tightly controlled, which is most commonly achieved by endog-
enous protease inhibitors (Rawlings et al., 2004). The cystatins
are natural inhibitors of the papain-like cysteine proteases of
family C1 (MEROPS; Rawlings et al., 2004), including the lyso-
somal enzymes cathepsin B, H, L, K, and S. Thus far, 12 human
cystatins (A, B, C, D, E/M, F, G, S, SN, SA, and H- and L-kinino-
gen) have been identified (Abrahamson et al., 2003), all of which
are evolutionary-related and belong to the protease inhibitor
family I25 (MEROPS; Rawlings et al., 2004). Cystatin C is the
most widespread cystatin, detected in all body fluids and tissues
investigated and present at concentrations sufficiently high to ef-
fectively inhibit any papain-like cysteine protease (Abrahamson
et al., 1986). Cystatin C functions as an emergency inhibitor for
cysteine protease activity during inflammation and tissue remod-960 Chemistry & Biology 15, 960–968, September 22, 2008 ª2008 Eeling, e.g., during vascular injury and in bone resorption (Koenig
et al., 2005; Leung-Tack et al., 1990; Turk et al., 2002). In addi-
tion, cystatin C is considered to take part in the innate immune
response by acting as a scavenger of cysteine proteases from
pathogenic microorganisms (Turk et al., 2002; Scharfstein,
2006; Bjo¨rck et al., 1990) and has also been implicated in various
diseases such as cerebral amyloid angiopathy (Levy et al., 2006)
andmetastasing cancer, andmay in this context serve as a puta-
tive biomarker (Kos et al., 2000).
The common and important human bacterial pathogen Strep-
tococcus pyogenes (or group A streptococcus) has evolved
a broad variety of molecular mechanisms to adapt to the dy-
namic environment in its human host (Cunningham, 2000). In
particular, two papain-like cysteine proteases are of importance:
the classical cysteine protease, SpeB, and the immunoglobulin
G (IgG) degrading protease, IdeS. SpeB has broad proteolytic
activity and degrades or activates numerous human and
bacterial proteins (Rasmussen and Bjo¨rck, 2002; von Pawel-
Rammingen and Bjo¨rck, 2003), while IdeS is highly specific in
its proteolytic activity recognizing only IgG as substrate (von
Pawel-Rammingen et al., 2002; Vincents et al., 2004). IdeS,
also described as Mac-1 (Lei et al., 2001), constitutes the first
member of a family of cysteine proteases (family C66) (Rawlings
et al., 2004), but despite little sequence similarity, the enzyme
adopts a typical papain-like structural fold (Wenig et al., 2004;
Agniswamy et al., 2006). The papain-like structure of IdeS
opened the possibility that cystatins, as natural inhibitors of
papain-like proteases, might inhibit the activity of this important
virulence factor. In fact, synthetic peptide derivatives mimicking
the N-terminal of cystatin C have previously been shown to effi-
ciently inhibit streptococcal cysteine proteases (Bjo¨rck et al.,
1989; von Pawel-Rammingen et al., 2002), indicating that the
protease inhibitor might be of importance for the innate immune
defense against streptococcal proteases. Because no natural
inhibitors of streptococcal cysteine proteases have yet been
identified, we screened human cystatins for inhibitory activity to-
ward the IgG endopeptidase IdeS. Unexpectedly, IdeS activity
was not inhibited by host protease inhibitors of the cystatin fam-
ily; instead, protease activity was markedly stimulated in the
presence of human cystatin C. Kinetic studies revealed that
the human protease inhibitor cystatin C efficiently accelerated
the enzymatic velocity of the streptococcal cysteine protease
IdeS and thus functions as a facultative cofactor for this bacteriallsevier Ltd All rights reserved
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ing an activating effect on a proteolytic enzyme and has im-
portant implications for the current view on protease-inhibitor
interactions.
RESULTS
Screening of Cystatins for Inhibitory Activity
Against IdeS
The papain-like structure fold of IdeS (Wenig et al., 2004; Ag-
niswamy et al., 2006) suggests that cystatinsmight act as natural
inhibitors of this important streptococcal virulence factor. There-
fore a panel of purified cystatins, human cystatin A, C, D, E/M, as
well as chicken cystatin and human kininogen were screened for
an effect on the IgG-endopeptidase activity of IdeS. Prior to the
experiment the inhibitory capacity of the protease inhibitors was
assessed by determining the capacity of the inhibitors to block
papain activity toward the synthetic substrate Na-benzoyl-L-ar-
ginine 4-nitroanilide (BAPA). All proteins efficiently inhibited pa-
pain activity at the concentrations used (Figure 1A). Putative ef-
fects of the protease inhibitors on IdeS activity were investigated
in an FPLC-based assay using human IgG as substrate as previ-
ously described (Vincents et al., 2004). Neither kininogen nor
cystatins A and D were found to have an effect on the activity
of IdeS, even when present in large excess, while cystatin E/M
showed some minor inhibition (Figure 1A) (Vincents et al.,
2004). In sharp contrast, human cystatin C exhibited a surprising
activating effect in that IdeS activity increased to more than
300% in the presence of cystatin C. This activating effect seems
to be restricted to human cystatin C, because chicken cystatin
was unable to stimulate (or inhibit) IdeS (Vincents et al., 2004).
To confirm the activating effect of cystatin C, a different standard
assay for determination of Ig-endopeptidase activity was em-
ployed (Gilbert et al., 1983). Subsequent to digestion of radiola-
beled IgG by IdeS, IgG cleavage products were separated by
SDS-PAGE, and relative IgG endopeptidase activity was deter-
mined as the ratio of radioactivity in the cleavage product to total
heavy chain radioactivity as previously described (A˚kesson et al.,
2006). Again, in the presence of cystatin C, a significant increase
in IdeS activity was observed (Figure 1B), confirming a stimulat-
ing effect of cystatin C on IdeS.
Enzymatic Characterization of Cystatin C Effects
on IdeS Hydrolysis of IgG
To clarify the specific action of human cystatin C on IdeS, en-
zyme kinetic studies were performed using isothermal titration
calorimetry (ITC). ITC methodology is based on the measure-
ment of heat from interactingmolecules e.g., binding and confor-
mational changes. In addition, the technique has proved useful
as an assay for enzymatic reactions by measurement of heat
Figure 1. Stimulation of IdeS Activity by
Cystatin C
(A) Human cystatins A (5 mM), C (10 mM), D (10 mM),
and E/M (5 mM) were tested for inhibitory action on
IdeS by preincubation in molar excess to the en-
zyme as indicated. The inhibitory capacity of the
cystatins was assayed using papain as a control
(gray bars). The results are related to the activities
of IdeS or papain in the absence of potential inhib-
itors, which were arbitrarily set to 100%. Experi-
ments were repeated with several different IdeS
preparations. The experimental variation for the
IdeS assay was up to 20% for cystatin A, D, and
E/M and up to 30% for cystatin C. For the papain
assay, utilizing a chromogenic substrate, the ex-
perimental variation was less than 5%. One repre-
sentative experiment out of four is shown.
(B) IgG-endopeptidase activity (black bars) and
papain activity (gray bars) in the presence of equi-
molar amounts of cystatin C. For determination of
IdeS activity, purified proteins were incubatedwith
125I- myeloma IgG1 as substrate and enzyme ac-
tivity was calculated as the ratio of radioactivity
in the cleavage product to total heavy chain radio-
activity. IdeS activity in the absence of cystatin C
was set to 100. All values are ± SD (n = 3). *p <
0.012, Student’s t test. The inhibitory capacity of
cystatin C was assayed using papain as a control
and the chromogenic BAPA as a substrate. Papain
activity in the absence of cystatin Cwas set to 100.
All values are ± SD (n = 3). **p < 0.001, Student’s
t test.
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Cystatin C Accelerates Bacterial Protease Activitydevelopment during hydrolysis, which is proportional to the
amount product formed (Todd and Gomez, .2001). For the char-
acterization of enzyme activity Vmax, Km, kcat, the specificity con-
stant, kcat/Km, and the specificity time, Km/Vmax, were deter-
mined at various concentrations of IdeS and cystatin C (Table
1). For IdeS at low concentration (0.1 mM), Vmax and pseudo-
Km values were estimated directly from the velocity curve to
26 nM/s and 45 mM, respectively (Table 1). Interestingly, at
this concentration IdeS displayed non-Michaelis-Menten kinet-
ics illustrated by the weakly sigmoidally shaped velocity curve
(Figure 2A), similar to results obtained from direct IgG hydrolysis
assays (Vincents et al., 2004). However, in the presence of 10 mM
or 20 mM cystatin C, an accelerated reaction was observed with
a more than 3- fold increased Vmax in the presence of 20 mM
cystatin C (Table 1). Interestingly, the Km values also increased,
to 73 mM at 10 mM cystatin C and to 65 mM at 20 mM cystatin C,
respectively. When the IdeS concentration was raised to 0.3 mM
(Figure 2B) and 1 mM (Figure 2C), the presence of cystatin C also
resulted in an increased Vmax value, though to a lesser extent
(2.2-fold and 1.3-fold, respectively) (Table 1). Again, Km values
at these concentrations were higher in the presence of cystatin
CwhencomparedwithKmvaluesobtainedwith IdeSalone (Table
1).Notably, Km valueswere found todecreasewith increasing en-
zyme concentration, independent of the presence or absence of
cystatin C (Table 1). Determination of the specificity constants
(kcat/Km) for IdeS under the different conditions clearly show an
improved enzyme performance in the presence of cystatin C at
lower IdeS concentrations, which is also reflected by consider-
ably shorter specificity times (Km/Vmax) at these concentrations.
At the higher IdeS concentration, however, where a smaller
increase in Vmax (1.3-fold) was observed, neither the specificity
constant nor the calculated specificity time indicated any stimu-
latory effect of cystatin C on IdeS activity (Table 1).
Cystatin C Binding to IdeS
To further strengthen the idea that cystatin C functions as a
cofactor for IdeS, we sought experimental evidence for an
Table 1. Enzyme Kinetic Parameters for IdeS Activity in the
Absence or Presence of Cystatin C
IdeS
(mM)
Cystatin
C (mM)
Vmax
(nM s1)
Km
(mM)
kcat
(s1)
kcat/Km
(s1 mM1)
Km/Vmax
(s)
0.1 — 26a 45a 0.26 5.8 1731
10 43 73 0.43 5.9 1714
20 80 65 0.8 12.3 789
0.3 — 39 34 0.13 3.8 868
20 86 47 0.29 6.1 552
1 — 63 11 0.06 5.7 178
20 85 21 0.09 4.0 246
IdeS activity was determined via an ITC-based assay. Vmax and Km were
estimated from plots of [S]/v against [S]. kcat was estimated from the
relationship of Vmax = kcat 3 [E ] assuming 100% activity of the enzyme.
The specificity time, Km/Vmax, specifies the time needed to hydrolyse all
the substrate if the enzyme acts under first-order conditions and sustain
the initial rate indefinitely (Cornish-Bowden, 1987).
a Under conditions when obvious non-Michaelis-Menten kinetics
occurred, Vmax and Km were estimated directly from the velocity plot of
v versus [S].962 Chemistry & Biology 15, 960–968, September 22, 2008 ª2008 EFigure 2. ITC-Kinetic Experiments of Cystatin C Effects on IdeS
Hydrolysis of IgG
Graphs show the enzymatic behavior of IdeS visualized by plots of v versus [S].
(A) Velocity plot of IdeS at 0.1 mM (B) and supplemented with cystatin C at
10 mM (:), and 20 mM (C) concentration. Inset shows the corresponding
[S]/v versus [S] plot, where 0.1 mM IdeS in the absence of cystatin C does
not follow Michaelis-Menten kinetics, but where Michaelis-Menten-like
kinetics are achieved by addition of cystatin C allowing estimation of Km and
Vmax.values.
(B) Velocity plot of IdeS at 0.3 mM (B) and supplemented with cystatin C at
20 mM (C) with inset of the corresponding [S]/v versus [S] plot from which
Km and Vmax were estimated.
(C) Velocity plot of IdeS at 1.0 mM (B) and supplemented with cystatin C at
20 mM (C), with inset of the corresponding [S]/v versus [S] plot from which
Km and Vmax values were estimated. Note that the shape of the velocity and
Hanes plots most likely reflects an average of several reaction pathways,
resulting in a nonideal linear fit.lsevier Ltd All rights reserved
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Cystatin C Accelerates Bacterial Protease Activityinteraction between the protease inhibitor and IdeS. Experi-
mental ITC samples were analyzed by size exclusion chroma-
tography (SEC) followed by immunochemical (enzyme-linked
immunosorbent assay [ELISA]) identification of cystatin C in
the collected fractions (Figure 3). To be able to detect possible
binding of cystatin C to intact IgG or IgG bound to IdeS, the en-
zymatically inactive IdeSC94S variant (Wenig et al., 2004) was
used in these experiments. Cystatin C alone eluted in fraction
27, in accordance with its molecular weight, when compared
to the elution profiles of a set of standard proteins. However,
when cystatin C was applied in a mixture with IdeSC94S, it could
be detected already in fraction 19 (Figure 3, blue curve), which
demonstrates complex formation of cystatin C with IdeSC94S.
Complex formation was not affected by the presence of IgG
(Figure 3, red curve), although some interaction between cysta-
tin C and IgG could be observed (Figure 3, green curve), imply-
ing different binding sites on cystatin C for IdeS and IgG. To
confirm these results, relevant samples were analyzed via
western blotting using a human cystatin C specific polyclonal
antiserum (Figure 3B).
Figure 3. Interaction between IdeS and Cystatin C
(A) Diagnostic ELISA was used to detect cystatin C complex formation with
IdeSC94S and IgG. Samples from ITC analysis were separated and fractionated
via SEC. Cystatin C alone (black curve) was seen to peak in fraction 27, but
elutes in complex with IdeSC94S (blue curve) or IgG and IdeSC94S (red curve)
in fraction 19 and fraction 14, respectively. A minor interaction of cystatin C
and IgG could also be observed (green curve).
(B) Western blot analysis of relevant SEC fractions using rabbit anti-cystatin C
antiserum. Note that fraction 17 in IdeSC94S/cystatin C is missing.Chemistry & Biology 15, 960–Interaction of Cystatin C and IdeS
Complex formation between IdeS and cystatin C was further
studied via surface plasmon resonance (SPR) measurements
in an attempt to gain insight into the mechanisms of stimulation
of IdeS activity by cystatin C. Cystatin C bound to immobilized
IdeS with high affinity, reflected in an equilibrium constant for
dissociation (KD) of approximately 10
7 to 5 3 108 M
(Figure 4A), whereas in contrast to gel filtration experiments (Fig-
ure 3, green curve), no binding of cystatin C to immobilized IgG
could be detected (Figure 4C). Importantly, binding of IdeS to im-
mobilized IgG was not affected by the presence of cystatin C, in-
dicating that the stimulatory effect of cystatin C on IdeS activity is
not at the level of substrate recognition (Figure 4C). Interestingly,
the best fit to the experimental sensorgrams was achieved with
a model assuming a heterogeneous immobilized ligand. IdeS
has previously been suggested to form homodimers (Agnisw-
amy et al., 2006). IdeS was found to interact with immobilized
IdeS with a KD of 1.7 mM, confirming homodimer formation of
IdeS (Figure 4B) and suggesting that both monomeric and di-
meric forms of IdeS are immobilized on the sensorchip surface.
To analyze whether the presence of cystatin C could affect di-
merization of IdeS, a series of SPR experiments were performed
using mixed analyte solutions containing varying concentrations
and different molar ratios of IdeS and cystatin C. The SPR exper-
iments revealed that cystatin C binding to IdeS does not interfere
with IdeS dimerization; instead, at a 1:1 molar ratio of IdeS and
cystatin C, the affinity for IdeS binding to immobilized IdeS in-
creased to 4 3 108 M (Table 2). Taken together, these data
demonstrate that cystatin C does not affect substrate recogni-
tion, but instead acts on the conformational state or stoichome-
try of the enzyme. This finding is confirmed by the fact that the
sensorgram obtainedwith equimolar amounts of IdeS and cysta-
tin C are best fitted to a two-state binding model, implying a con-
formational change. However, due to the complexity of interac-
tions, additional experiments are certainly required to elucidate
the precise mechanism of cystatin C action on IdeS.
Stimulation of IdeS Activity Ex Vivo
The unexpected finding of a dedicated cysteine protease inhib-
itor acting as a facultative cofactor for a protease raised the
question of whether cystatin C cofactor activity might be of rele-
vance in a physiological environment. The majority of strepto-
coccal infections are localized to the mucosal epithelium of the
pharynx, and saliva is all-prevalent in the mouth and throat
region. Cystatin C is present in saliva at concentrations of ap-
proximately 0.1 mM (Abrahamson et al., 1986), and IdeS is readily
secreted during bacterial growth in saliva (Shelburne et al.,
2005). Therefore, a putative accelerated activity of IdeS in saliva
samples was investigated by time-course experiments using ra-
diolabeled IgG as a substrate. However, although the assay was
clearly suitable for detection of IdeS activity in a complex phys-
iological environment, it appeared that the method reached its
limitations when employed for measurements of differences of
initial enzyme velocities. Nevertheless, despite large interexper-
imental variations, IgG endopeptidase activity in fractionated hu-
man saliva, depleted in low-molecular-weight proteins such as
cystatins, appeared clearly lower compared with IdeS activity
in native saliva (Figure 5A–5C, open and filled squares). This was
also true when saliva was treated by incubation with solid phase968, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 963
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Cystatin C Accelerates Bacterial Protease Activitycoupled Cm-papain, which specifically binds and thereby inacti-
vates cystatins (Figure 5D). Incubation of IdeS with the remaining
fraction showed a marked reduction of immediate IgG endo-
peptidase activity compared with the native saliva sample
Figure 4. SPR Analysis of Cystatin C-IdeS Interactions and IdeS
Homodimer Formation
(A) Cystatin C binding to immobilized IdeSC94S. Serial dilutions of cystatin C
from 6 to 0.75 mM were used. A representative sensorgram is shown.
(B) IdeSC94S binding to immobilized IdeSC94S. Serial dilutions of IdeSC94S from
20 to 0.15 mM were used. A representative sensorgram is shown.
(C) IdeSC94S binding to immobilized IgG in the presence or absence of equimo-
lar amounts of cystatin C. IdeSC94S and cystatin C at concentrations from 0.1
to 9 mM were used. A single representative sensorgram obtained with IdeS
alone and IdeSC94S and cystatin C at a concentration of 5 mM is shown. No
binding of cystatin C to immobilized IgG could be detected.964 Chemistry & Biology 15, 960–968, September 22, 2008 ª2008 E(Figure 5D, open and filled squares), and similar results were ob-
tained using saliva that was preincubated with protein G-cou-
pled antibodies against cystatin C (Figure 5E, open and filled
squares). Most importantly, when cystatin C (100 nM) was added
to treated saliva samples, IdeS activity was restored to levels
similar to the activity observed in native saliva (Figures 5D and
5E, filled triangles). To further extend the investigation of an ac-
celerating effect of cystatin C in physiological samples, IdeS
activity was determined in plasma samples supplemented with
various amounts of cystatin C. IdeS activity in these experiments
was detected by the presence of a diagnostic 31 kDa cleavage
product (von Pawel-Rammingen et al., 2002) and quantified
using Fc-specific antibodies. Clearly, the presence of cystatin
C stimulated IdeS activity in plasma samples in a dose-depen-
dent manner, reflected by an increase in band intensity (CP)
in the presence of increasing concentrations of cystatin C
(Figure 5F). Estimates of Fc product bands (CP) by densitometry
indicate an approximately doubled rate of product formation in
the presence of cystatin C, which is in accordance with the in-
creased velocity rates obtained in ITC kinetic experiments (Table
1, Figure 2). The fact that cystatin C does exert its stimulatory ac-
tivity also in physiological environments, such as human saliva
and blood plasma, clearly suggests the relevance of this mech-
anism in vivo.
DISCUSSION
In the present study, the ubiquitous human protease inhibitor
cystatin C was identified as a natural, facultative cofactor for
the streptococcal IgG endopeptidase IdeS. Although the en-
zyme structurally resembles target enzymes for cystatin C, the
inhibitor fails to block enzymatic activity of IdeS and instead ef-
ficiently accelerates the enzymatic velocity of this cysteine pro-
tease. This finding is an example of a protease inhibitor having
an activating effect on a proteolytic enzyme and is in accordance
with our previous suggestion that IdeS might be able to interact
with an effector molecule (Vincents et al., 2004). The sole sub-
strate of IdeS, IgG, is present in vast amounts in the circulation
(70–90 mM). Upon secretion from invading streptococci, initially
high IdeS concentrations are achieved in the vicinity of the bac-
teria, allowing the protease to function as an effective defense
toward specific antibodies in the circulation. This view is sup-
ported by the finding of a Michaelis-Menten-like velocity curve
at high IdeS concentrations (Figure 2C), demonstrating an opti-
mally functioning enzyme. At these high IdeS concentrations
cystatin C does apparently not improve the performance of
IdeS according to our kinetic results (compare Kcat/Km) (Table
1). However, after secretion and radial diffusion, an increasing
Table 2. Dissociation Constants for Binding of IdeS and IgG
Analyte
Concentration
(mM)
Ligand KD
(mM) IdeS
Concentration
(mM)
Ligand KD
(mM) IgG
IdeS 0.15–20 3.4 0.11–9 2.5
Cystatin C 0.75–6 0.056 5 ND
IdeS +
(Cystatin C)
0.75–3 0.0439 0.11–9 2.15
ND, not detectable.lsevier Ltd All rights reserved
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(A–E) Time-course of IdeS activity in human saliva or saliva treated to deplete cystatins. Relative cleavage (cpm cleavage product [CP]/total heavy chain cpm) is
shown. IdeS was incubated with 125I-IgG andmyeloma IgG1 in 25% human saliva. (A–C) Time course of IdeS activity in human saliva (-) of three different donors
(A–C), or the respective human saliva diminished for cystatins by ultrafiltration (,). (D) IdeS activity in native saliva samples of one donor (filled squares) and
corresponding human saliva treatedwith Cm-papain (,), andCm-papain treated saliva supplementedwith 100 nMcystatin C (:). (E) IdeS activity in native saliva
samples of another donor (-) and corresponding human saliva depleted for cystatin C by immunopreciptiation (,), and cystatin C depleted saliva supplemented
with (100 nM) cystatin C (:). H, heavy chain; CP, cleavage product.
(F) IdeS activity in diluted human plasma, supplemented with cystatin C. Aliquots of the reaction were separated via SDS-PAGE and analyzed via western blotting
using Fc specific secondary antibody. Final cystatin C concentrations are indicated. CP, cleavage product; IgGHc, heavy chain. Purified IgG1 was used as cleav-
age control.dilution of IdeS in the environment will occur that will not favor an
effective protection of the bacteria as the enzyme functions sub-
optimally. Under these conditions, cystatin C, which is abundant
in host liquids and tissue, acts as a cofactor to the bacterial pro-
tease and accelerates IdeS activity to increase enzyme activity
also at a distance from the pathogen. This is reflected by clearly
increased Vmax and reduced specificity times in the presence of
cystatin C. Such a strategy to counteract the immune system at
a distance (i.e., remote from the bacteria), is not uncommon to
group A streptococci. For instance, streptococcal IgG-binding
proteins, in complex with IgG, have the ability to activate and
consume complement at a distance, thereby avoiding comple-
ment activation at the bacterial surface (Berge et al., 1997).
Thus, as a biological consequence of the widespread distribu-
tion of cystatin C, the pathogen has the ability to maintain IdeS
activity and thus, an effective cleavage of specific IgG, even at
low IdeS concentrations, for instance during the early stages of
an infection when bacterial numbers are low.Chemistry & Biology 15, 960–The molecular mechanism for IdeS activity is complex since
it involves several different reactions steps leading to product
formation both in the presence and absence of cystatin C. A
schematic view of such possible reaction pathways has been
described as the general-modifier-mechanism (Botts and
Morales, 1953). When E, S, and A represent IdeS, IgG, and
cystatin C, respectively, a possible reaction pathway could be
described as:
ð1Þ
IdeS activity has been suggested as an allosteric enzyme (Vin-
cents et al., 2004) and to function in a dimeric form (Agniswamy
et al., 2006), notions, which are supported by data presented in968, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 965
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kinetics. The decrease of Km with increasing concentration of
IdeS appears unusual since Km is generally meant to be indepen-
dent of the enzyme concentration. However, when considering
an overall hydrolysis pathway involving dimerization of IdeS,
ð2Þ
the equilibrium (E + E$ E2) could be a rate-limiting step of the
reaction. Dimerization of IdeS (E2) should be concentration
dependent and if the KD for dimer formation is high, this could
explain our results for effects on Km, when the IdeS concentra-
tion is raised. In fact, the earlier reported KD value for dimer for-
mation in vitro is very high (250 mM) (Agniswamy et al., 2006),
compared to IdeS concentrations of 50 nM detected in in vitro
laboratory cultures (von Pawel-Rammingen et al., 2002), and
the putative presence of a dimeric form of IdeSmight offer an ex-
planation for the kinetic behavior of the enzyme observed in ITC-
kinetic experiments. SPR experiments confirmed a KD for dimer
formation in the mM range, albeit approximately 100-fold lower,
compared with the earlier reported values. Including cystatin C
into these considerations it can be assumed that cystatin C af-
fects the dimer equilibrium (E + E$ E2) of IdeS. This hypothesis
is supported by SPR analysis, indicating an increased affinity for
IdeS-IdeS interactions in the presence of cystatin C. Although
SPR experiments indicate that cystatin C affects IdeS stoichom-
etry and/or its conformational state, the data have to be inter-
preted with caution and further studies are required to dissect
the precise molecular mechanism of cystatin C action on IdeS.
However, most importantly, cystatin C does not affect substrate
recognition of IdeS.
It is intriguing that a bacterial pathogen has evolved a papain-
like cysteine protease that utilizes a highly abundant host prote-
ase inhibitor to accelerate its enzymatic activity. We report a
protease inhibitor exhibiting an accelerating rather than inhibiting
effect on its putative target protease. This finding is not only
a profound example of coevolutionary processes between bac-
terial proteases and the human host defense, but also suggests
a fine balance between inhibition and stimulation of proteolytic
systems. The current finding questions that the result of protease
inhibitor interactions solely has to be inhibition of the enzymatic
activity of a protease. Because protease inhibitors are used as
therapeutic agents (e.g., as antiviral drugs [Deeks et al., 1997])
and have been suggested as a treatment for microbial infections,
the finding of an enzyme-activating rather than inhibiting prote-
ase inhibitor should have broad implications for the future evalu-
ation of therapeutic drugs targeting proteolytic enzymes.
SIGNIFICANCE
S. pyogenes infections are clinically highly significant and in-
clude throat and skin infections, as well as life-threatening
conditions, such as toxic shock. The survival of S. pyogenes
in its human host depends on the ability of the bacteria to
avoid the antimicrobial actions of the innate and adaptive
immune systems, and to modulate the inflammatory re-
sponses induced during the course of an infection. Immuno-966 Chemistry & Biology 15, 960–968, September 22, 2008 ª2008globulin G (IgG) plays a central role in the human immune re-
sponse. To avoid the detrimental actions of specific IgG,
S. pyogenes has developed an IgG endopeptidase, IdeS,
that is specific for the hinge region of human IgG and medi-
ates streptococcal survival in the presence of opsonizing
antibodies. Proteases are highly involved in the establish-
ment of streptococcal infection, and several proteases are
important virulence factors. Endogenous proteolytic activity
in humans has to be tightly controlled by protease inhibitors
to prevent cellular damage by unwanted proteolytic activi-
ties. Cystatin C is considered the physiologically most im-
portant inhibitor of these cysteine proteases. Cystatin C is
a biomarker for renal function, but serum cystatin C levels
have been also been correlated with vascular disease. The
present study reveals an unexpected role for cystatin C in
stimulating, rather than counteracting, protease activity.
This is the first report of an activating role of a dedicated
protease inhibitor toward a putative target protease. This
finding does not only change the view on the relation of pro-
tease inhibitor and target proteases, but should also initiate
a re-evaluation of the role of cystatin C.
EXPERIMENTAL PROCEDURES
Proteins and Peptides
Recombinant IdeS and IdeSC94S were expressed in Escherichia coli and puri-
fied as described elsewhere (von Pawel-Rammingen et al., 2002; Wenig et al.,
2004). Cystatins A, C, D, and E/M were produced in E. coli or Baculovirus ex-
pression systems as described previously (Abrahamson et al., 1988; reviewed
in Abrahamson et al., 2003). Papain (Sigma, St. Louis, MO) and human gamma
globulin (Kabi Pharmacia, Sweden) were repurified as described previously
(Hall et al., 1995; Vincents et al., 2004), while human polyclonal IgG and
myeloma IgG1 (kappa) were purchased from Sigma.
Collection of Human Saliva
Saliva production in healthy volunteers was stimulated by chewing 1 g of par-
affin for 5 min. Twenty-milliliter saliva samples were collected, cleared by cen-
trifugation (3200g for 30 min) and sterilized by filtration (Millipore Stericup,
0.2 mm). Saliva samples were kept at 4C and used within 24 h after collection.
Saliva was fractionated using ultrafiltration centrifugal filter units with a nominal
molecular weight limit of 30 kDa (Ultrafree-MC, Millipore). Saliva samples were
depleted for cystatins either by absorption with Cm-papain (Anastasi et al.,
1983; Brillard-Bourdet et al., 1998) or by immunoprecipitation with polyclonal
rabbit antibodies directed against cystatin C. Antibodies were purified and
coupled to protein G sepharose (AmershamBioscience) according to theman-
ufacturer’s instructions.
Inhibitor Scan
IdeS (1 mM) and papain (0.5 mM) were preincubated with molar excess of
human cystatin A, C, D, or E/M for 20 min at 37C or room temperature, re-
spectively. IdeS activity was assessed by addition of 100 mM human IgG
and analysis by separation of hydrolysis products on a routine FPLC assay
as previously described (Vincents et al., 2004). The inhibitory capacity of cys-
tatins was assayed using papain as control, in a chromogenic assay by the ad-
dition of BAPA (Na-benzoyl-L-arginine 4-nitroanilide, Sigma) as described
(Abrahamson, 1994). The resulting enzymatic activity in the presence of cysta-
tin was expressed as the percentage of IdeS or papain activity in absence of
cystatin that was arbitrarily set to 100%.
Quantification of IdeS Activity using Radiolabeled IgG
Quantification of IdeS endopeptidase activity was determined as described
previously for microbial IgA proteases (Gilbert et al., 1983). Briefly, 1 pmol of
the enzyme was incubated with 105 cpm of 125I-IgG and 2.5 mg of unlabeled
myeloma IgG1 in 20 mM Tris-HCl buffer (pH 6.8) with 20% human saliva orElsevier Ltd All rights reserved
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ple buffer and incubation at 95C for 5 min. IgG chains and IgG cleavage prod-
ucts were separated on 12% SDS-PAGE and visualized by staining with Coo-
massie Blue (R-250) (USBChemicals). Protein bands corresponding to the IgG
heavy chain (H), IgG light chain (L), and the IdeS cleavage product (CP) were
excised from the gel for determination of radioactivity. Samples were counted
in a LKB Wallac Compugamma counter, and IdeS activity was calculated as
the ratio of radioactivity in the cleavage product, CP to total heavy chain radio-
activity (CP + H).
Quantification of IdeS Activity in Human Plasma
Quantification of IdeS endopeptidase activity in human plasma was deter-
mined via western blotting. Briefly, IdeS (50 mM) was diluted 1:2000 and pre-
incubated in phosphate-buffered saline containing 1 mM dithiothreitol. The
reaction mixture was added to a 1:10 dilution of human plasma supplemented
with increasing amounts of cystatin C. Incubation was continued for 20 min at
37C. Reactions were stopped by the addition of SDS sample buffer and incu-
bation at 95C for 5 min. IgG chains and IgG cleavage products were sepa-
rated on Novex gels (Invitrogen) and subjected to western blot analysis. As
a primary antibody, rabbit anti-human IgG-CH2 (DAKO) was used, followed
by incubation with HRP-conjugated swine anti-rabbit IgG (DAKO) and visual-
ization using ECL Plus (Pierce). Protein bands corresponding to the IgG heavy
chain (IgGHc) and the IdeS cleavage product (CP) are indicated. IdeS activity
was quantified by densiometric determination of CP band intensity using NIH
image software.
Enzyme Kinetic ITC Studies
Enzyme kinetic studies were performed using isothermal titration calorimetry
(ITC), a well-documented methodology for use in enzymology (Spink and
Wadso¨, 1976;Watt, 1990; Morin and Freire, 1991; Lonhienne et al., 2001; Bian-
coni, 2007; Todd and Gomez, 2001; Willemoes and Sigurskjo¨ld, 2002). In brief,
the method is based on measuring the heat (Q) generated during enzymatic
hydrolysis of substrate, which is proportional to the enthalpy of the reaction
and thus the amount of product formed. Heat generation is measured as
a function of time (t), where v and dQ/dt are directly proportional (v = d[P]/dt =
(1/Vol. 3 DHapp) dQ/dt). Measurement at different substrate concentrations
was achieved by continuous injection of substrate in large excess into the re-
action cell, thus creating pseudo-first order reaction (Todd and Gomez, 2001).
All ITC experiments were performed using a VP-ITC microcalorimetry instru-
ment (Microcal, Northampton, MA) equilibrated at 26C. The reference cell
was filled with degassed deionized water. All reagents were exhaustively dia-
lyzed against 0.1 M Bis-Tris buffer (pH 6.5) at 26C, (I = 154 mM adjusted with
NaCl), degassed for 5-10min, and kept 1–2Cbelow the experimental temper-
ature. The sample cell was filled with the buffer for measurement of the dilution
heat of the substrate or with IdeS (0.1–1.0 mM) alone or in the presence of cys-
tatin C (10–20 mM). The syringe was filled with human IgG (617– 900 mM) and
purged at least two times. Before starting the reaction, the calorimeter was
equilibrated at 26C with mechanical stirring (310 rpm) and a preinjection
baseline of 300–600 s was monitored prior to the first injection. The enzymatic
reaction was started by injection of IgG (5–10 mL) into the IdeS solution, fol-
lowed by 24–39 injections increasing the substrate concentration stepwise.
The time spacing between substrate injections was 60–300 s and optimized
so that a stable line with thermal power at a lower level than the baseline
was established during equilibrium. This period reflects the steady state of
the enzymatic reaction and substantiates initial velocities. To determine enzy-
matic rates, the thermal power change was averaged over the 15–30 s imme-
diately preceding an injection to reduce the noise from the dilution of substrate.
Obtained values were subtracted from the thermal power of the baseline and
divided by the DH of the reaction. To estimate DHapparent for the hydrolysis re-
action, human IgG (5–20 mM) was injected into IdeS (0.5–1 mM). Spacing time
was set to 600 s between each injection to ensure the thermal power to return
to the baseline level as an indication for complete hydrolysis of the substrate.
From integration of the peaks, we estimated the average DHapparent of the hy-
drolysis reaction to be2285 cal/mole in absence of cystatin C and2353 cal/
mole in the presence of cystatin C (20 mM) (data not shown). All data were
visually inspected and analyzed using the Origin software package (Microcal
Instruments, Northampton, MA).Chemistry & Biology 15, 960–9SPR Experiments
SPR experiments were performed using a BIAcore X-100 biosensor (GE
Healthcare). Purified IdeSC94S was immobilized on a CM-5 sensor chip using
standard amino coupling chemistry according to the manufacturer’s instruc-
tions. IdeSC94S was injected at a concentration of 0.15 mM in 5 mM sodium ac-
etate buffer (pH 5.5) until approximately 1200 resonance units (RU) were cou-
pled. IgG was injected at a concentration of 0.03 mM in 10 mM sodium acetate
buffer (pH 5.0) until approximately 1200 RU were coupled. After coupling, the
remaining activated groups at the sensor chip surface were blocked with eth-
anolamine. Binding experiments were performed at flow rate of 30 ml/min and
at different analyte concentrations (0.75 mM to 6 mM for cystatin C; 0.11 mM to
20 mM for IdeSC94S). Blank values obtained from control experiments without
coupled ligand were subtracted from experimental responses obtained from
the active surface. Binding and kinetic data were derived from obtained data
using the BIAevaluation software (GE Healthcare).
ELISA
Samples from ITC analysis of human IgG (55 mM), titrated into inactive IdeSC94S
(5 mM) in the presence or absence of human cystatin C (20 mM) were subjected
to SEC (Superdex 75 10/30, Amersham Biosciences) and fractionated in vol-
umes of 500 mL. The fractions were analyzed via ELISA (Olafson et al., 1988)
modified to utilize a SA-HRP conjugate (DAKO) for detection of the biotinylated
monoclonal antibody as detecting antibody. Recombinant human cystatin C
(Abrahamson et al., 1988) was used for appropriate calibration curves.
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